Enfermedad cardiovascular y metabólica en pacientes infectados por el virus de la inmunodeficiencia humana

  • William Alejandro Camargo-Ariza Universidad industrial de Santander
  • Silvia Juliana Galvis-Blanco Universidad Industrial de Santander
  • Édgar Felipe Gualdrón-Rincón Universidad Industrial de Santander
  • Jorge Mario Palmezano-Díaz Universidad Industrial de Santander.

Resumen

Desde la instauración de la terapia antiretroviral, la morbimortalidad asociada al síndrome de la inmunodeficiencia adquirida ha disminuido drásticamente y la infección por el Virus de la Inmunodeficiencia Humana se ha convertido en una enfermedad crónica. Sin embargo, con la introducción del tratamiento antiretroviral para el control de la enfermedad se ha observado un aumento en la prevalencia de enfermedad cardiovascular en este grupo, convirtiéndose éste en un motivo de especial preocupación. Consecuentemente, la evaluación y prevención de la enfermedad cardiovascular se ha tornado de suma importancia y debe evaluarse de manera individual y rutinaria en estos pacientes. El objetivo de este artículo es hacer una revisión de las principales complicaciones cardiovasculares y metabólicas con el fin de consolidar los posibles hallazgos a los que se enfrenta el clínico al momento de un abordaje integral de un paciente seropositivo para el virus de inmunodeficiencia humana. MÉD.UIS. 2017;30(2):45-54.

Palabras clave: Terapia Antirretroviral Altamente Activa. Enfermedades Cardiovasculares. Enfermedades metabólicas. VIH.

Descargas

La descarga de datos aún no está disponible

Biografía del autor

William Alejandro Camargo-Ariza, Universidad industrial de Santander
Estudiante de IX nivel de Medicina. Universidad Industrial de Santander. Escuela de Medicina. Facultad de Salud. Bucaramanga. Santander. Colombia.
Silvia Juliana Galvis-Blanco, Universidad Industrial de Santander

Estudiante de IX nivel de Medicina. Universidad Industrial de Santander. Escuela de Medicina. Facultad de Salud. Bucaramanga. Santander. Colombia.

Édgar Felipe Gualdrón-Rincón, Universidad Industrial de Santander
Estudiante de VII nivel de Medicina. Universidad Industrial de Santander. Escuela de Medicina. Facultad de Salud. Bucaramanga. Santander. Colombia
Jorge Mario Palmezano-Díaz, Universidad Industrial de Santander.

Residente de Medicina Interna. Universidad Industrial de Santander. Servicio de Medicina Interna. Hospital Universitario de Santander. Bucaramanga. Santander. Colombia.

Citas

1. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen
L, et al. Severe premature coronary artery disease with protease
inhibitors. Lancet. 1998;351(9112):1328.

2. Hemkens LG, Bucher HC. HIV infection and cardiovascular
disease. Eur Heart J. 2014;35(21):1373–81.

3. Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra
L, Hartford F, et al. CD4+ Count-Guided Interruption of
Antiretroviral Treatment. NEJM. 2006;355(22):2255–65.

4. Risso GD. Enfermedad cardiovascular en sujetos con VIH / SIDA
Cardiovascular disease in patients with HIV / AIDS. Rev Fed Arg
Cardiol. 2012;41(4):235–48.

5. ONUSIDA. Informe Mundial: ONUSIDA, Informe sobre la
epidemia mundial de SIDA. 2013. p. 274.

6. Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA.
Hoja informativa 2015. 2015; p. 1–8.

7. Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA. El
SIDA en cifras 2015. 2015; p. 1-12.

8. Teva I, Bermúdez MP, Ramiro MT, Buela-Casal G. Situación
epidemiológica actual del VIH/SIDA en Latinoamérica en la
primera década del siglo XXI: Análisis de las diferencias entre
países. Rev Med Chil. 2012;140(1):50–8.

9. Ministerio de Salud y Protección Social de Colombia. Boletin
Epidemiológico semanal. Semana epidemiológica número 22 de
2016. Colombia; 2016;2016.

10. Ministerio de Salud y Protección Social de Colombia. Resumen
de situación de la epidemia por VIH / SIDA en Colombia 1983 a
2011. 2012; p. 1-15.

11. Instituto Nacional de Salud I, Ministerio de Salud y Proteccion
Social. Protocolo de vigilancia en Salud Pública. VIH - SIDA.
2014. p.43.

12. Nuñez RL, Paola S, Mira Á. Boletín epidemiológico, situación del
VIH / SIDA Colombia 2013. 2013.

13. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199–206.

14. Zou W, Berglund L. HIV and highly active antiretroviral therapy:
dyslipidemia, metabolic aberrations, and cardiovascular risk.
Prev Cardiol. 2007;10(2):96–105.

15. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. I nflammation, coagulation and cardiovascular disease in
HIV-infected individuals. PLOS ONE. 2012;7(9):e44454.

16. Hemkens LG, Bucher HC. HIV infection and cardiovascular
disease. Eur Heart J. 2014;35(21):1373–81.

17. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE,
et al. Plasma Levels of Soluble CD14 Independently Predict
Mortality in HIV Infection. J Infect Dis. 2011;203(6):780–90.

18. Pirš M, Jug B, Eržen B, Šabović M, Karner P, Poljak M, et al.
Relationship between markers of endothelial dysfunction and
inflammation and subclinical atherosclerosis in HIV-infected
male patients below 55 years of age. Acta Dermatovenerologica
Alp Pannonica Adriat. 2014;23(3):49–52.

19. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell
A, et al. Carotid Intima-Media Thickness Among Human
Immunodeficiency Virus–Infected Patients Without Coronary
Calcium. Am J Cardiol. 2012;109(5):742–7.

20. Mashinya F, Alberts M, Van geertruyden J-P, Colebunders R.
Assessment of cardiovascular risk factors in people with HIV
infection treated with ART in rural South Africa: a cross sectional
study. AIDS Res Ther. BioMed Central. 2015;12(1):42.

21. Nsagha DS, Assob JCN, Njunda AL, Tanue EA, Kibu OD, Ayima
CW, et al. Risk Factors of Cardiovascular Diseases in HIV/AIDS Patients on HAART. Open AIDS J. 2015;9(1):51–9.

22. Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin
LA, Murdoch D, et al. HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era: What We Know and Best Directions for Future Research. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S40–53.

23. Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM,
Velazquez EJ. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. JACC Heart Fail 2015;3(8):579–90.

24. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E,
Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy
in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res. 2007;5(1):129–37.

25. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement
in HIV infected people in Yaounde, Cameroon. Postgrad Med J.
2002;78(925):678–81.

26. Shah MR. The Broad Spectrum of HIV-Related Cardiovascular
Disease*. JACC Heart Fail. Elsevier Inc; 2015;3(8):600–2.

27. Butt AA, Chang C-C, Kuller L, Goetz MB, Leaf D, Rimland D, et
al. Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease. Arch Intern Med. 2011;171(8):737–43.

28. Duan M, Yao H, Hu G, Chen XM, Lund AK, Buch S. HIV Tat
Induces Expression of ICAM-1 in HUVECs: Implications for miR-221/-222 in HIV-Associated Cardiomyopathy. PLoS One. 2013;8(3):1–11.

29. Twu C, Liu NQ, Popik W, Bukrinsky M, Sayre J, Roberts J, et al.
Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci U S A. 2002;99(22):14386–91.

30. Fiala M, Popik W, Qiao JH, Lossinsky AS, Alce T, Tran K, et al.
HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol. 2004;4(2):97–107.

31. Currie PF, Boon NA. Immunopathogenesis of HIV-related heart
muscle disease: Current perspectives. AIDS. 2003;17 Suppl 1:S21–8.

32. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D.
Impact of Highly Active Antiretroviral Therapy in HIV-positive
Patients with Cardiac Involvement. J Infect. 2000 May;40(3):282–4.

33. Luo L, Ye Y, Liu Z, Zuo L, Li Y, Han Y, et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int J STD AIDS. 2010;21(12):814–8.

34. Currie PF, Goldman JH, Caforio AL, Jacob AJ, Baig MK, Brettle RP, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart. 1998;79(6):599–604.

35. Patel VB, Sacoor Z, Francis P, Bill PLA, Bhigjee AI, Connolly C.
Ischemic stroke in young HIV-positive patients in Kwazulu-Natal,
South Africa. Neurology. 2005;65(5):759–61.

36. Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of Cardiovascular
Disease in an Aging HIV Population: Where Are We Now? Curr HIV/AIDS Rep. 2015;12(4);375–87.

37. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute
myocardial infarction rates and cardiovascular risk factors among
patients with human immunodeficiency virus disease. J Clin
Endocrinol Metab. 2007,92(7):2506–12.

38. Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay CL.
Association between HIV infection, antiretroviral therapy, and
risk of acute myocardial infarction: a cohort and nested casecontrol
study using Québec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53.

39. Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E,
Kraemer KL, et al. HIV infection and the risk of acute myocardial
infarction. JAMA Intern Med. 2013;173(8):614–22.

40. Silverberg MJ, Leyden WA, Xu L, Horberg MA, Chao CR, Towner
WJ, et al. Immunodeficiency and Risk of Myocardial Infarction
Among HIV-Positive Individuals With Access to Care. JAIDS J Acquir Immune Defic Syndr. 2014;65(2):160–6.

41. Paisible A-L, Chang C-CH, So-Armah KA, Butt AA, Leaf DA,
Budoff M, et al. HIV infection, cardiovascular disease risk factor
profile, and risk for acute myocardial infarction. J Acquir Immune
Defic Syndr. 2015;68(2):209–16.

42. Tabib A, Leurox C, Mornex J LR. Accelerated coronary
atherosclerosis and arteriosclerosis in young humanimmunodeficiency-virus-positive patients. Coron Artery Dis.
2000;11(1):41–6.

43. Mehta NJ KI. HIV-associated coronary artery diseas. Angiology.
2003;54(3):269–75.

44. Khunnawat C, Mukerji S, Havlichek D, Touma R, Abela GS.
Cardiovascular manifestations in human immunodeficiency
virus-infected patients. Am J Cardiol. 2008;102(5):635–42

45. Klein D, Hurley LB, Quesenberry CP Jr SS. Do protease inhibitors
increase the risk for coronary heart disease in patients with HIV-1
infection?. J Acquir Immune Defic Syndr. 2002;30(5):471–7.

46. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram
V, et al. Risk of cardiovascular disease from antiretroviral therapy
for HIV: a systematic review. PLoS One. 2013;8(3):e59551

47. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A,
et al. Clinical features of acute coronary syndromes in patients
with human immunodeficiency virus infection. Circulation.
2004;109(3):316–9.

48. Perello R. Clinical presentation of acute coronary syndrome in
HIV infected adults: a retrospective analysis of a prospectively
collected cohort. Eur J Int Med. 2011;22(5):485–8.

49. Benjamin LA, Bryer A, Emsley HCA, Khoo S, Solomon T, Connor
MD. HIV infection and stroke: Current perspectives and future
directions. Lancet Neurol. 2012;11(10):878–90.

50. Edwards NJ, Grill MF, Choi HA, Ko NU. Frequency and Risk
Factors for Cerebral Arterial Disease in a HIV/AIDS Neuroimaging
Cohort. Cerebrovasc Dis [Internet]. 2016;41(3-4):170–6. Available
from: URL: http://www.karger.com/?doi=10.1159/000442755

51. Sico JJ, Chang CC, So-Armah K, Justice AC, Hylek E, Skanderson
M, et al. HIV status and the risk of ischemic stroke among men.
Neurology. 2015;84(19):1933–40.

52. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr
Hypertens Rep. 2000;2(5):478–81.

53. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA,
et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953–60.

54. De Socio GVL, Bonfanti P, Martinelli C, Ricci E, Pucci G, Marinoni M, et al. Negative influence of HIV infection on daynight blood pressure variability. J Acquir Immune Defic Syndr. 2010;55(3):356–60.

55. Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez
EJ, et al. Hypertension and obesity as cardiovascular risk factors
among HIV seropositive patients in Western Kenya. PLoS One. 2011;6(7):e22288.

56. Mateen FJ, Kanters S, Kalyesubula R, Mukasa B, Kawuma E, Kengne AP, et al. Hypertension prevalence and Framingham risk
score stratification in a large HIV-positive cohort in Uganda. J
Hypertens. 2013;31(7):1372–8.

57. Maur R, Bortman G. Hipertensión arterial pulmonar asociada a
infección por el virus de la inmunodeficiencia humana. Insuf Card. 2007;2(1):41–2.

58. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C,
Ghofrani A, et al. Updated clinical classification of pulmonary
hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34-41.

59. Morris A, Crothers K, Beck JM, Huang L. An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases. Proc Am Thorac Soc. 2011;8(1):17–26.

60. Reinsch N, Buhr C, Krings P, Kaelsch H, Kahlert P, Konorza T, et
al. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: Results of the HIVHEART Study. HIV Med. 2008;9(7):550–6.

61. Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin
LA, Murdoch D, et al. HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era. J Acquir Immune Defic Syndr. 2014;67(Suppl 1):S40–53.

62. Barnett CF, Hsue PY. Human Immunodeficiency Virus-Associated Pulmonary Arterial Hypertension. Clin Chest Med. 2013;34(2):283–92.

63. Parikh RV, Ma Y, Scherzer R, Heringer AS, Macgregor JS, Martin
JN, et al. Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection. PLoS One. 2016;11(1):e0146355.

64. Quezada M, Toro R, López M, Lennie V, Eulalia Valencia LP de I y
LMC. La Endotelina -1 y la función del ventrículo derecho: Nuevo
marcador en población VIH positivo con Hipertensión Arterial Pulmonar. Rev Española Cardiol. 2014;67(Supl 1:885):2–3.

65. Husain NE, Ahmed M. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV/AIDS. 2014;7:1-10.

66. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn
PA. Comorbidity-related treatment outcomes among HIV-Infected
adults in the Bronx, NY. J Urban Health. 2011;88(3):507–16.

67. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al.
Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82.

68. Grinspoon S, Carr A. Cardiovascular risk and bodyfat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48-62.

69. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz
N, et al. Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. Clin Infect Dis. 2001;32:130–9.

70. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand
M, et al. Predicting the short-term risk of diabetes in HIV-positive
patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc. 2012;15(2):1–10.
Publicado
2017-06-29
Cómo citar
CAMARGO-ARIZA, William Alejandro et al. Enfermedad cardiovascular y metabólica en pacientes infectados por el virus de la inmunodeficiencia humana. REVISTA MÉDICAS UIS, [S.l.], v. 30, n. 2, p. 45-54, jun. 2017. ISSN 1794-5240. Disponible en: <http://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6425>. Fecha de acceso: 21 ago. 2017
Sección
Revisión de tema